Hendrian Dwikoloso SOEBAGJO, Hidayat SUJUTİ, Hasan MACHFOED, Sutiman Bambang SOEMİTRO

Retinoblastoma Hücrelerinin Çoğalmasında FasL Ekspresyonu: Fas Atağının Mekanizması

Amaç: Bu çalışmanın amacı artan FasL ekspressyonu ile retinoblastom hücrelerindeki proliferasyon artışı arasındaki ilişkiyi incelemektir. Materyal ve Metod: Ki-67, CDK4 ve FasL ekspresyon değerlerini incelemek için parafin blok yapılmış 30 retinoblastom örneğinin protein ekspresyon değerleri immünohistokimyasal analiz ile belirlendi. Bulgular: 30 retinoblastom örneği arasından %33.3 ünde (10 örnek) FasL ekspresyonu yok iken %36,8 inde güçlü bir ekspresyon vardır. %53.3 (16 örnek) örnekte CDK4 ekspresyonunun zayıf olduğu görülürken Ki-67 ekspresyonunun yüksek olduğu tespit edilmiştir. FasL ekspresyonu yüksek oranda CDK4 ekspresyonu ile ilgilidir (r:0,363, p:0,048). Aynı zamanda CDK4 ün ekspresyonu da Ki-67 ekspresyonuyla ilgilidir (r:0,601, p: 0,000). Sonuç: FasL atağı mekanizmasındaki artan FasL ekspresyonu retinoblastoma hücrelerinin proliferasyonunu indüklemektedir

Anahtar Kelimeler:

FasL, proliferasyon, atak, retinoblastom

Expression of FasL in Proliferation of Retinoblastoma Cells: A Mechanism Fas Counterattack

Purpose: The aim of this study were to determine the association of increasing of FasL with increasing proliferation of retinoblastoma cells. Materials and Methods: The protein expression was analyzed in 30 retinoblastoma samples from paraffin block using immunohistochemical method for evaluation of FasL, CDK4, and Ki-67 expression. Results: Among 30 retinoblastoma samples, FasL expression majority was negative in 33.3 % (10 samples) and strong in 36,8 % (11 samples). CDK4 majority 53,3% was weak expression and Ki-67 was high expression also in 53,3% (16 samples). The expression of FasL was significantly related to CDK4 (r: 0.363; p: 0.048). The CDK4 was also significantly related to Ki-67 expression (r: 0.601; p: 0.000). Conclusion: The increasing of FasL on the mechanism Fas counterattack induces proliferation of retinoblastoma cells.

Keywords:

FasL, proliferation, counterattack, retinoblastoma.,

PDF

___

Divan J, Lawry IR, Dunsmore MA, Parsons JA. p53 and p21waf-1 Expression Correlates with Apoptosis or Cell Survival in Poorly Differentiated, but not WellDifferentiated, Retinoblastomas. Cancer Research. 2001;61:3157-63.

Khrisnakumar S, Kandalam M, Mohan A, Iyer A, Vankatesan N, Biswas J, Shanmugam MP. Expression of Fas Ligand in Retinoblastoma. American Cancer Society. 2004;101:1672-6.

Sehu KW. Ophthalmic Pathology. An Illustrated Guide for Clinican. British Library, Blackwell Publishing. 2005.

Sitorus RS, Gumay S, Der Valk PV. The apoptosis paradox in retinoblastoma. Natural compounds and their role in apoptotic cell signaling pathways. Ann.N.Y. Acad.Sci. 2005;1171:77-86.

Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. British Journal of Cancer. 1999;81:747–51.

Kumar V, and Stricker TP. Neoplasia in Robin dan Cotran, Pathologic Basic of Diasease, 8th. Ed. Saunders Elsevier. 2010;259-327.

Urruticoechea A, Smith IE, and Dowsett M. Proliferation Marker Ki-67 in Early Breast Cancer. J Clin Oncol. 2005;23:7212-20.

Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early kanker payudara: where are we now? Ann Oncol. 2005;16:1723-27.

Bennett MW, O’Connell J, O’Sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999;44:156–62.

Maher S, Toomey D, Condron C, and BouchierHayes D. Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. J.Imun.Cell.Biol. 2001;80:131-7.

Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford). 2006;45:26-30

Lumongga F. Apoptosis. Departemen Patologi Anatomi Fakultas Kedokteran Universitas Sumatera Utara. USU Repository. 2008.

Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of fas ligand by shedding. J.Nat. Med. 1998;4(1):31-6.

Houston A. and O’Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Current Opinion in Pharmacology. 2004;4:321-6.

Tong Q, Zheng L, Tang S, Li S, Jiang G, Cai J, Liu Y, Ruan Q. Expression of Fas and FasL in human neuroblastoma and its clinical significance. World J Pediatr. 2007;3:209-13.

An H, Beckmann MW, Reifenberger G, Bender HG, and Niederacher D. Gene Amplification and Overexpression of CDK4 in Sporadic Breast Carcinomas Is Associated with High Tumor Cell Proliferation. American Journal of Pathology. 1999;154:113-8

Ben-Izhak, O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H, and Sabo E. Ki67 Antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology. 2002;41:519-25.

Lee YB, Kyung Kim E, Park HJ, Cho BK, Park YM, Kim JW, et al. Expression of Fas and Fas ligand in primary cutaneous squamous cell carcinoma in association with grade of tumor differentiation. Int.J.Dermatol. 2013;52:1092-7.

Shimizu M, Kondo M, Ito Y, Kume H, Suzuki R, Yumaki K. Soluble fas and fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. cancer detection and prevention. Elsevier. 2004. doi:1016/j.cdp.2004.09.001.

Perabo F.G.E., Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, et al. Bladder cancer cells acquire competent mechanisms to escape Fasmediated apoptosis and immune surveillance in the course of malignant transformation. British Journal of Cancer. 2001;84:1330–8.

Zhou, JH, Chen HZ, Ye F, Lu WG, and Xie X. Fasmediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncology Reports. 2006;16:307

Trihia H, Murray S, Price K, Gelbert RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its associations with grading systems, clinical parameters, and other prognostic factors– a surrogate marker? Cancer. 2003;97:1321-31

Nabi U, Nagi AH, Sami W. Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J.Ayub Med Coll Abbottabad. 2008;20:44

Lazar D, Taban S, Sporea I, Dema A, Corianu M, Lazar E, Goldis A, Vernic C. Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Romanian Journal of Morphology and Embryology. 2010;51:655–61

Pryczynicz, A, Guziñska-Ustymowicz K, and Kemona A. Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochemica Et Cytobiologica. 2010;48:425-9.

Zhang W, Ding EX, Wang Q, et al. Fas Ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol. 2005;11:3632-5.

Mitsiades N, Yu W, Poulaki V, Tsokos M, and Stamenkovic I. Matrix Metalloproteinase-7-mediated Cleavage of Fas Ligand Protects Tumor Cells from Chemotherapeutic Drug Cytotoxicity. Cancer Research. 2001;61:577–81.

Vargo-Gogola T, Crawford HC, Fingleton B, and Matrisian LM. Identification of novel matrix metalloproteinase-7(matrilysin) cleavage sites in murine and human Fas ligand. Archives of Biochemistry and Biophysics. 2002;408:155–61.

Webb SD, Sherratt JA, and Fish RG. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. Mathematical Biosciences. 2002;179:113–29.

Schroter M, Peli J, Hahne M, Tschopp J, Reichmann E. Fas-dependent tissue turnover is implicated in tumor cell clearance. Oncogene. 2000;19:1794-1800.

Kurooka M, Nuovo GJ, Cagliuri MA, Nabel GJ. Cellular localization and function of Fas Ligand (CD95L) in tumors. Cancer Res. 2002;62:1261-5.

Zhu, Q, Liu JY, Xu HW, et al. Mechanism of counterattack of colorectal cancer cell by Fas/FasL system. World J Gastroenterol. 2005;11:6125-9.

Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res. 2000;6:3560-4.

Yazışma Adresi / Address for Correspondence: Dr. Dr. Hendrian D. Soebagjo Medical Faculty of Airlangga University Department of Ophthalmology Dr. Soetomo Hospital Jl. Mayjen. Prof. Dr. Moestopo no 6-8 Surabaya, East Java, INDONESIA E-mail: hendriands@yahoo.com G eliş tarihi/Received on : 06.01.2014

Kabul tarihi/Accepted on: 14.02.2014